BHVNBiohaven Ltd.

Healthcare
$12.09-16% 1Y

Price

-16%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 5% of companies
8/100
Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for BHVN today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. We are advancing our innovative portfolio of therapeutics, leveraging our proven drug development experience and multiple proprietary drug development platforms. On October 3, 2022, Biohaven Pharmaceutical Holding Company Ltd. (the “Former Parent”) completed the distribution to holders of its common shares of all of our outstanding common shares and the spin-off of Biohaven Ltd. from the Former Parent (the “Separation”).

In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR

P/En/a
Market value$2.31B
1 year-16%
5 yearsn/a

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 9, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Sep 10, 2026Biohaven Ltd. (the “Company,” “we” or “our”) is providing updates to the BHV-7000 program. We refer you to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 for a description of the BHV-7000 program.Other event · Form 8-K
  2. Aug 26, 2026License Agreement On August 26, 2026, Biohaven Bioscience Ireland Limited (“BBIL”), a wholly owned subsidiary of Biohaven Ltd. (the “Company”), entered into a License Agreement (the “License Agreement”) with SK Biopharmaceuticals Co., Ltd. (“SKBP”)Material agreement entered · Form 8-K
  3. Aug 10, 2026Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

On our screens:Most shorted stocks

Biotechnology

Ranks #127 of 196 by RyuScore

Compare peers
MLYS+4.4%
Mineralys Therapeutics, Inc.
NRIX+0.68%
Nurix Therapeutics, Inc.
PHVS+0.05%
Pharvaris N.V.
SLBT-1.3%
SL Science Holding Limited
MRVI+3.7%
Maravai LifeSciences Holdings, Inc.
AUPH+2.7%
Aurinia Pharmaceuticals Inc.